ORIC PHARMACEUTICALS INC (ORIC) Stock Earnings & Estimates
NASDAQ:ORIC - US68622P1093 - Common Stock
10.66 USD
+0.14 (+1.33%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A -44.98% | N/A 725.84% | N/A 290.41% | N/A 283.26% | N/A 121.50% | N/A 52.38% | ||||||||
| EBITDA YoY % growth | -21.47M | -27.54M -28.27% | -48.38M -75.67% | -77.97M -61.16% | -90.8M -16.46% | -109.97M -21.11% | -141.89M -29.03% | N/A -2.37% | N/A 5.25% | N/A 48.87% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -22.37M | -28.57M -27.72% | -49.35M -72.73% | -78.87M -59.82% | -91.77M -16.36% | -111M -20.95% | -143M -28.83% | N/A -5.35% | N/A -8.08% | N/A -7.91% | N/A -2.49% | N/A 20.78% | N/A 139.97% | N/A 691.38% | N/A 75.94% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -6.22 | -2.07 66.72% | -2.25 -8.70% | -1.96 12.89% | -1.82 7.14% | N/A 4.58% | N/A 5.05% | N/A -0.93% | N/A 10.89% | N/A 34.32% | N/A 166.49% | N/A 481.10% | N/A 73.71% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.40 18.61% | -0.37 26.76% | -0.34 19.86% | -0.34 26.65% | -0.41 -2.30% | -0.44 -17.88% |
| Revenue Q2Q % growth | ||||||
| EBITDA Q2Q % growth | -39.258M -5.53% | -37.877M 2.60% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -39.726M -4.54% | -37.833M 5.42% | -38.492M -16.64% | -39.865M -2.22% | -52.493M -32.14% | -28.257M 25.31% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.47 -4.44% | -0.45 | -0.02 | -4.01% |
| Q1 2025 Q2Q % growth | -0.42 -13.51% | -0.52 | 0.10 | 19.44% |
| Q4 2024 Q2Q % growth | -0.51 -4.08% | -0.52 | 0.01 | 1.05% |
| Q3 2024 Q2Q % growth | -0.49 -11.36% | -0.49 | 0.00 | -0.41% |
| Q2 2024 Q2Q % growth | -0.45 10.00% | -0.42 | -0.03 | -7.05% |
| Q1 2024 Q2Q % growth | -0.37 30.19% | -0.44 | 0.07 | 16.82% |
| Q4 2023 Q2Q % growth | -0.49 5.77% | -0.50 | 0.01 | 1.24% |
| Q3 2023 Q2Q % growth | -0.44 30.16% | -0.47 | 0.03 | 6.61% |
| Q2 2023 Q2Q % growth | -0.50 1.96% | -0.58 | 0.08 | 13.87% |
| Q1 2023 Q2Q % growth | -0.53 10.17% | -0.55 | 0.02 | 3.81% |
| Q4 2022 Q2Q % growth | -0.52 10.34% | -0.55 | 0.03 | 4.95% |
| Q3 2022 Q2Q % growth | -0.63 -34.04% | -0.56 | -0.07 | -11.60% |
| Q2 2022 Q2Q % growth | -0.51 10.53% | -0.61 | 0.10 | 16.69% |
| Q1 2022 Q2Q % growth | -0.59 -31.11% | -0.58 | -0.01 | -1.78% |
| Q4 2021 Q2Q % growth | -0.58 30.95% | -0.58 | 0.00 | -0.62% |
| Q3 2021 Q2Q % growth | -0.47 -14.63% | -0.59 | 0.12 | 20.89% |
| Q2 2021 Q2Q % growth | -0.57 -11.76% | -0.50 | -0.07 | -13.55% |
| Q1 2021 Q2Q % growth | -0.45 89.91% | -0.49 | 0.04 | 8.52% |
| Q4 2020 Q2Q % growth | -0.84 | -0.47 | -0.37 | -77.36% |
| Q3 2020 Q2Q % growth | -0.41 | -0.40 | -0.01 | -1.98% |
| Q2 2020 Q2Q % growth | -0.51 | -0.40 | -0.11 | -26.21% |
| Q1 2020 Q2Q % growth | -4.46 | -0.27 | -4.19 | -1,556.27% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 9.91% | 24.81% | 4.25% | 6.91% |
| Revenue | N/A | N/A | N/A | N/A |